Type 2 Diabetes and ADP Receptor Blocker Therapy

Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment plate...

Descripción completa

Detalles Bibliográficos
Autores principales: Samoš, Matej, Fedor, Marián, Kovář, František, Mokáň, Michal, Bolek, Tomáš, Galajda, Peter, Kubisz, Peter, Mokáň, Marián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707344/
https://www.ncbi.nlm.nih.gov/pubmed/26824047
http://dx.doi.org/10.1155/2016/6760710
_version_ 1782409294952529920
author Samoš, Matej
Fedor, Marián
Kovář, František
Mokáň, Michal
Bolek, Tomáš
Galajda, Peter
Kubisz, Peter
Mokáň, Marián
author_facet Samoš, Matej
Fedor, Marián
Kovář, František
Mokáň, Michal
Bolek, Tomáš
Galajda, Peter
Kubisz, Peter
Mokáň, Marián
author_sort Samoš, Matej
collection PubMed
description Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy.
format Online
Article
Text
id pubmed-4707344
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-47073442016-01-28 Type 2 Diabetes and ADP Receptor Blocker Therapy Samoš, Matej Fedor, Marián Kovář, František Mokáň, Michal Bolek, Tomáš Galajda, Peter Kubisz, Peter Mokáň, Marián J Diabetes Res Review Article Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy. Hindawi Publishing Corporation 2016 2015-12-28 /pmc/articles/PMC4707344/ /pubmed/26824047 http://dx.doi.org/10.1155/2016/6760710 Text en Copyright © 2016 Matej Samoš et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Samoš, Matej
Fedor, Marián
Kovář, František
Mokáň, Michal
Bolek, Tomáš
Galajda, Peter
Kubisz, Peter
Mokáň, Marián
Type 2 Diabetes and ADP Receptor Blocker Therapy
title Type 2 Diabetes and ADP Receptor Blocker Therapy
title_full Type 2 Diabetes and ADP Receptor Blocker Therapy
title_fullStr Type 2 Diabetes and ADP Receptor Blocker Therapy
title_full_unstemmed Type 2 Diabetes and ADP Receptor Blocker Therapy
title_short Type 2 Diabetes and ADP Receptor Blocker Therapy
title_sort type 2 diabetes and adp receptor blocker therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707344/
https://www.ncbi.nlm.nih.gov/pubmed/26824047
http://dx.doi.org/10.1155/2016/6760710
work_keys_str_mv AT samosmatej type2diabetesandadpreceptorblockertherapy
AT fedormarian type2diabetesandadpreceptorblockertherapy
AT kovarfrantisek type2diabetesandadpreceptorblockertherapy
AT mokanmichal type2diabetesandadpreceptorblockertherapy
AT bolektomas type2diabetesandadpreceptorblockertherapy
AT galajdapeter type2diabetesandadpreceptorblockertherapy
AT kubiszpeter type2diabetesandadpreceptorblockertherapy
AT mokanmarian type2diabetesandadpreceptorblockertherapy

Ejemplares similares